Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2009 Oct;19(5):493-9.
doi: 10.1089/cap.2008.0126.

An open study of adjunct OROS-methylphenidate in children who are atomoxetine partial responders: II. Tolerability and pharmacokinetics

Paul Hammerness  1 , Anna Georgiopoulos, Robert L Doyle, Linsey Utzinger, Mary Schillinger, Marykate Martelon, Kerry Brodziak, Joseph Biederman, Timothy E Wilens
Affiliations
Clinical Trial

An open study of adjunct OROS-methylphenidate in children who are atomoxetine partial responders: II. Tolerability and pharmacokinetics

Paul Hammerness et al. J Child Adolesc Psychopharmacol. 2009 Oct.

Abstract

Objective: The aim of this study was to evaluate the tolerability of adding OROS methylphenidate (MPH) to children who are partial responders to atomoxetine (ATMX) in the treatment of attention-deficit/hyperactivity disorder (ADHD).

Methods: This was a two-phase, 7-week, open study in children aged 6-17 years. Phase 1 initiated ATMX for a minimum of 4 weeks. Phase 2 entered partial responders to ATMX and added OROS MPH to their regimen. Safety was assessed using blood pressure and heart rate measurements, electrocardiogram readings, AEs, laboratories, and ATMX levels.

Results: Fifty subjects who were partial responders to ATMX received the combination therapy, with 41 subjects completing the entire protocol. As reported elsewhere (Wilens et al., 2009 ), OROS MPH added to partial responders of ATMX was accompanied by a 40% reduction in the ADHD rating scale score and improvements in executive functioning. However, the combination of ATMX plus OROS MPH was associated with greater rates of insomnia, irritability, and loss of appetite compared to ATMX alone. A small significant increase in diastolic blood pressure was observed during adjunctive OROS MPH, with no clinically meaningful changes in electrocardiogram (ECG) parameters during the study. ATMX levels and liver function tests did not significantly change during the combination treatment.

Conclusion: Adjunct OROS MPH in ATMX partial responders yielded an additive adverse effect burden in this short-term study. Further controlled research with larger samples of children is warranted.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Mean levels of laboratories for ATMX monotherapy and with adjunct OROS MPH. ATMX = Atomoxetine; MPH = methylphenidate.
FIG. 2.
FIG. 2.
ATMX Serum Levels for ATMX monotherapy and with adjunct OROS MPH. ATMX = Atomoxetine; MPH = methylphenidate.
See this image and copyright information in PMC

References

    1. Bangs ME. Jin L. Zhang S. Desaiah D. Allen AJ. Read HA. Regev A. Wernicke JF. Hepatic events associated with atomoxetine treatment for attention-deficit hyperactivity disorder. Drug Saf. 2008;31:345–354. - PubMed
    1. Brown TE. Atomoxetine and stimulants in combination for treatment of attention deficit hyperactivity disorder: Four case reports. J Child Adolesc Psychopharmacol. 2004;14:129–136. - PubMed
    1. Carlson GA. Dunn D. Kelsey D. Ruff D. Ball S. Ahrbecker L. Allen AJ. A pilot study for augmenting atomoxetine with methylphenidate: safety of concomitant therapy in children with attention-deficit/hyperactivity disorder. Child Adolesc Psychiatry Ment Health. 2007;1:10. - PMC - PubMed
    1. DeVane CL. Markowitz JS. Carson SW. Boulton DW. Gill HS. Nahas Z. Risch SC. Single-dose pharmacokinetics of methylphenidate in CYP2D6 extensive and poor metabolizers. J Clin Psychopharmacol. 2000;20:347–349. - PubMed
    1. Donner R. Michaels MA. Ambrosini PJ. Cardiovascular effects of mixed amphetamine salts extended release in the treatment of school-aged children with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2007;61:706–712. - PubMed

Publication types

MeSH terms